|Bid||1.97 x 2000|
|Ask||2.20 x 2000|
|Day's range||1.90 - 2.04|
|52-week range||0.19 - 6.06|
|PE ratio (TTM)||N/A|
|Earnings date||18 May 2017 - 19 May 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.00|
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.